Age-Related Macular Degeneration

Aviceda Therapeutics announced the dosing of the first patient in the second part of its phase 2/3 SIGLEC trial investigating AVD-104 to treat geographic atrophy secondary to age-related macular degeneration.

Ascendis Pharma announced the launch of Eyconis, a company formed with the exclusive rights to develop, manufacture and commercialize Ascendis’ TransCon ophthalmology assets, according to a press release.

Tilak Healthcare has released positive data from its TIL002 study of the OdySight mobile app, a vision-monitoring tool for patients with retinal diseases.

Aviceda Therapeutics announced positive safety and efficacy outcomes from part 1 of its phase 2/3 SIGLEC trial for AVD-104, which is being evaluated in patients with geographic atrophy secondary to age-related macular degeneration.

LumiThera announced the EUROLIGHT registry study will evaluate the safety, efficacy and biomarkers of photobiomodulation treatment for dry age-related macular degeneration.

WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Ferhina S. Ali, MD, MPH, presents real-world data from the FARETINA-AMD study investigating faricimab for the treatment of neovascular age-related macular degeneration.

WAILEA, Hawaii — In this Healio video perspective from Hawaiian Eye 2024, Sunir J. Garg, MD, FACS, FASRS, discusses 96-week data investigating aflibercept 8 mg for the treatment of neovascular age-related macular degeneration.

ROME — A deep learning algorithm developed at University of California, Los Angeles, showed superior performance compared with other algorithms and human graders in detecting early biomarkers of age-related macular degeneration progression.

Healio’s top retina items last year included the FDA approvals of Syfovre for geographic atrophy and Eylea HD for wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.